.@NIH: This trial supports using CDCM on day (4 hours after the initial dose) to reduce the SARS-CoV-2 viral load in saliva. For long-term effect (7 days), CDMC appears to provide a modest benefit compared with placebo in reducing viral load in saliva. https://t.co/VeXd3zmlEG https://t.co/XKq6YfQx0d